Merck Archives

News and Trends 16 Aug 2022

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech company working on a new investigational class of engineered circular RNA (oRNA) therapies, are to collaborate on discovering, developing, and commercializing multiple programs, including vaccines and therapeutics, in the areas of infectious diseases and oncology. Under the terms of the […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

Immutep reports positive data from cancer study

Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease, has announced new interim data from second-line NSCLC (non-small cell lung cancer) patients (Part B) in its phase 2 TACTI-002 trial. The data was presented at the IASLC 2022 World Conference of Lung Cancer (WCLC 2022) in Vienna, Austria, and […]

August 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

BioMed X Institute and Merck start new oncology research project

BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of […]

August 1, 2022 - 3 minutesmins - By Jim Cornall

circulating tumor cells, cancer, clinical trials

News and Trends 28 Jul 2022

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […]

July 28, 2022 - 3 minutesmins - By Liza Laws

Best in Biotech 28 Jul 2022

Five companies personalizing treatments with 3D printed drugs

There has been a noticeable shift in recent years towards the personalization of medicine, with the pharmaceutical industry showing interest in pills that are tailored to a patient’s needs. Here are five companies that are leveraging 3D printing to produce customizable drugs. Conventional drug production relies on large-scale batch manufacturing, which is very efficient at […]

July 28, 2022 - 5 minutesmins - By Omnia Ibrahim

decentralized trial virtual clinical trial

News and Trends 29 Jun 2022

Global call for scientists and inventors to form new startup

A fourth start-up but the first of its kind sees some high-profile companies join forces in a hunt for new global research talent. AION Labs, an Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) are focusing their start-up on the ‘prediction of clinical trial outcome in biomarker-stratified cancer patient […]

June 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 May 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

May 5, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Aug 2021

Artios’ €129M Series C Pushes Limits of DNA Repair in Cancer

The UK firm Artios Pharma raised a huge Series C round last week in one of many efforts to develop cancer drugs that target the DNA repair systems of our cells. Artios Pharma bagged €129M (£110M) last week in a venture capital round led by the US-based firms Omega Funds and TCG X. The proceeds […]

August 6, 2021 - 4 minutesmins - By Anita Chakraverty

brain cancer glioblastoma divide and conquer

News and Trends 23 Jan 2020

Merck Spinout Bags €15M Series A to Tackle Cancer and Fibrosis

iOnctura, a spinout from Merck KGaA, has raised €15M to take its cancer and fibrosis drugs to phase I clinical trials. The Series A round was co-led by new investors INKEF Capital and VI Partners. The founding investor of iOnctura, M Ventures — the corporate venture arm of Merck — also contributed to the round, […]

January 23, 2020 - 2 minutesmins - By Jonathan Smith

rhino northern white embryo conservation

News and Trends 17 Jan 2020

International Collaboration on Brink of Resurrecting Northern White Rhinos

An international collaboration called BioRescue has taken a step forward in bringing back the Northern White Rhino with the creation of three embryos, which it hopes to bring to term in a surrogate in the coming months. The BioRescue team, including researchers based at the Leibniz Institute for Zoo and Wildlife Research, Germany, extracted egg […]

January 17, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2019

Update: First Ever Ebola Vaccine Gets US and EU Approval

Update (20/12/2019): After getting conditional approval in Europe in November, Merck has received FDA approval for its Ebola vaccine, the first to be approved in both regions. Published on 13/11/2019 The big pharma company Merck has won a conditional marketing authorization from the European Commission for the Ebola vaccine Ervebo, the first to be approved. […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

acne s biomedic skinbiotherapeutics skin microbiome

News and Trends 8 Oct 2019

UK Company and Merck Team Up to Develop Vaccines Based on the Microbiome

Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based on delivering live bacteria to the gut. The partners will develop vaccines against three undisclosed conditions. As well as an undisclosed upfront fee for each condition, 4D Pharma will be eligible to receive up to €316.5M ($347.5M) in developmental milestones. […]

October 8, 2019 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us